Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Fineline Cube Dec 30, 2025
Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Fineline Cube Dec 30, 2025
Company Deals

Shenzhen TargetRx Raises $50M in Series C Financing for Global Clinical Trials

Fineline Cube Jan 23, 2025

China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of...

Company Drug

Haisco’s HSK44459 Approved for Clinical Trials in Behcet’s Disease

Fineline Cube Jan 23, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving clinical trial approval from...

Company Deals

Fosun’s Plan to Take Henlius Private Fails After Shareholder Vote

Fineline Cube Jan 23, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its plan...

Company Drug

Belief BioMed’s BBM-D101 Receives FDA Approval for DMD Clinical Trial

Fineline Cube Jan 23, 2025

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced receiving clinical trial approval from...

Company Medical Device

Roche’s cobas liat STI Assay Panels Gain FDA Approval and CLIA Waiver

Fineline Cube Jan 23, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced receiving approval from the US...

Company Drug

United Laboratories’ UBT251 Approved for Phase II Trials in Chronic Kidney Disease

Fineline Cube Jan 23, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced receiving approval from the...

Company Drug

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Fineline Cube Jan 23, 2025

France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval in the European Union...

Company Deals

Eli Lilly and Merck Launch Consortium for Innovative Drug Manufacturing

Fineline Cube Jan 23, 2025

US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have...

Company Deals

Akeso Biopharma Receives Development Payment for PD-L1 Monoclonal Antibody

Fineline Cube Jan 22, 2025

China-based Akeso Biopharma (HKG: 9926) has announced receiving a drug collaboration development payment from compatriot...

Company Deals

Shanghai Bao Pharmaceuticals Launches IPO to Advance Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2025

China-based Shanghai Bao Pharmaceuticals Co., Ltd., a high-end biopharmaceuticals developer, has announced its initial public...

Company Deals

Degron Therapeutics Secures $20M Series A+ for Molecular Glue Drug Development

Fineline Cube Jan 22, 2025

China-based Degron Therapeutics, a specialist in molecular glue-based drugs, has reportedly raised over USD 20...

Company Drug

FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial

Fineline Cube Jan 22, 2025

France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US...

Company Drug

Johnson & Johnson’s Spravato Approved as Monotherapy for Major Depressive Disorder

Fineline Cube Jan 22, 2025

US-based Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Spravato (esketamine) CIII nasal...

Company Drug

CD Biopharma Initiates Phase I Trial for CD-001 in Advanced Solid Tumors

Fineline Cube Jan 22, 2025

Suzhou-based tumor immunotherapy specialist CD Biopharma has announced the first subject dosing of a Phase...

Company Medical Device

Kehua Bioengineering Gains NMPA Approval for Gene Polymorphism Detection Kits

Fineline Cube Jan 22, 2025

China-based Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022) has announced receiving marketing approvals from the...

Company Drug

Humanwell’s HWH340 Receives Clinical Approval for Prostate Cancer Treatment

Fineline Cube Jan 22, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug...

Company Deals

Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange

Fineline Cube Jan 22, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...

Company Medical Device

Acotec’s Vericor-S2 Coronary Microcatheter Approved by NMPA

Fineline Cube Jan 22, 2025

Acotec Scientific Holdings Ltd (HKG: 6669) has announced that its Vericor-S2 coronary microcatheter has received...

Company Deals

Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent

Fineline Cube Jan 22, 2025

Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...

Policy / Regulatory

Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism

Fineline Cube Jan 21, 2025

President Donald Trump has signed an executive order indicating the withdrawal of the United States...

Posts pagination

1 … 159 160 161 … 603

Recent updates

  • Broncus Medical Acquires Valgen Stake from Venus for $15 Million
  • CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug
  • Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China
  • Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
  • Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.